A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation

International Journal of Hematology

Volumn 86, Issue 2, 2007, Pages 186-192

  Puig, Noemí ^a   De La Rubia, Javier ^a   Jarque, Isidro ^a   Salavert, Miguel ^a   Montesinos, Pau ^a   Sanz, Jaime ^a   Martín, Guillermo ^a   Sanz, Guillermo ^a   Cantero, Susana ^a   Lorenzo, Ignacio ^a   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Autologous stem cell transplantation; Chemoprophylaxis; Fluoroquinolones; Infectious complications

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; NYSTATIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; BACTERIAL INFECTION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; PNEUMONIA; PYREXIA IDIOPATHICA; SOLID TUMOR; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; FEMALE; FEVER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREMEDICATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 34548755612     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0633     Document Type: Article

References (38)

1. Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and marrow transplantation activity in Europe 1997. Bone Marrow Transplant. 1999;24:231-245.
2. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 1996;18:265-271.
3. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:143-147.
4. Watanabe T, Takaue Y, Abe T, Matsunaga K, Saito S, Hirao A. Early infectious complications after peripheral blood item cell autografts in children. Med Pediatr Oncol. 1991;19:100-105.
5. D'Antonio D, Iacone A, Pierelli L, Bonfini T. Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. The Grupo Italiano di Studio per la Manipolazione Cellulare in Ematologica. Eur J Clin Microbiol Infect Dis. 1995;14:552-556.
6. Weaver CH, Schwartzberg LS, Hainsworth J, Greco FA, Li W, Buckner CD. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 1997;19:671-678.
7. Reich G, Mapara MY, Reichardt P, Dörken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001;27:525-529.
8. Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma and multiple myeloma. Ann Hematol. 2002;81:374-377.
9. Su-Peng Yeh, Chiu CF, Lo WJ, et al. Low infectious morbidity in patients with heavily pretreated hematological malignancies receiving autologous peripheral blood stem cell transplantation without antimicrobial prophylaxis. Ann Hematol. 2003;82:24-29.
10. Sanz MA, López J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotical therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrobial Chemotherapy. 2002;50:79-88.
11. Ascioglu S, Rex JH, de Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
12. De la Rubia J, Saavedra S, Sanz GF, et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:21-25.
13. Reich G, Cornely OA, Sandherr M, et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomized, multicentre trial. Br J Haematol. 2005;130:265-270.
14. Sezer O, Eucker J, Bauhuis C, et al. Patients with malignant lymphomas experience a higher rate of documented infections than patients with breast cancer alter high-dose chemotherapy with autologous peripheral item cell transplantation. Ann Hematol. 2000;79:627-630.
15. Kern W, Kurrle E. Ofloxacin versus trimethoprim-sulfametoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection. 1991;19:73-80.
16. Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med. 1996;125:183-190.
17. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23:795-805.
18. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer - is it justified? Clin Infect Dis. 1997;25:346-348.
19. Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003;37:1643-1648.
20. National Nosocomial Infections Surveillance System report: data summary from January 1992 - June 2001, issued August 2001. Am J Infect Control. 2001;29:404-421.
21. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection. 2000;28:278-281.
22. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-750.
23. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis. 2002;34:1469-1474.
24. Solano C, Gutiérrez A, MartÌnez F, et al. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam. Bone Marrow Transplant. 2005;36:59-65.
25. Bucaneve G, Micozzi A, Manichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977-987.
26. Reuter S, V. Kern W, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40:1087-1093.
27. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergency of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-687.
28. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;39:520-524.
29. Nivison-Smith I, Bradstock K, Dodds AJ, Hawkins PA, Szer J. Haemopoietic stem cell transplantation in Australia and New Zealand, 1999-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. Intern Med J. 2005;35:18-27.
30. Jantunen E, Itala M, Lehtinen T, et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted recipients. Eur J Haematol. 2006;76:245-250.
31. Lyman, GH. Guidelines of the national comprehensive cancer network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Nat Comp Cancer Network. 2005;3:557-571.
32. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol. 1997;99:933-938.
33. Ojeda E, García-Bustos J, Aguado MJ, et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant. 1999;24:601-607.
34. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol. 1997;15:451-457.
35. Schmitz N, Ljungman P, Cordonnier C, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant. 2004;34:955-962.
36. Celebi H, Akan H, Akcaglayan E, Üstün C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant. 2000;26:211-214.
37. Salazar R, Sola C, Maroto P, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem-cell transplantation. Bone Marrow Transplant. 1999;23:27-33.
38. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients. A meta-analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-3246.